North America Antibody Drug Conjugates Market to 2030 - By Size, Share, Growth by End User and Forecast

1. Introduction

1.1 Business Market Insights Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:

4. North America Antibody Drug Conjugates Market Landscape

4.1 Market Overview

4.2 Porter's Five Forces Analysis

4.2.1 Bargaining Power of Suppliers
4.2.2 Bargaining Power of Buyers
4.2.3 Threat of New Entrants
4.2.4 Competitive Rivalry
4.2.5 Threat of Substitutes

4.3 Ecosystem Analysis

4.3.1 Raw Material Suppliers
4.3.2 Manufacturers
4.3.3 Distributors/Suppliers
4.3.4 End Users

5. North America Antibody Drug Conjugates Market – Key Market Dynamics

5.1 Growth Drivers

5.1.1 Strategic Investments by Key Players

5.2 Market Opportunities

5.2.1 Expansion into New Indications

5.3 Future Trends

5.3.1 Expanding Clinical Trial Pipeline

5.4 Impact of Drivers and Restraints

6. North America Antibody Drug Conjugates Market Regional Analysis

6.1 North America Antibody Drug Conjugates Market Overview

6.2 North America Antibody Drug Conjugates Market Revenue 2020-2030 (US$ Million)

6.3 North America Antibody Drug Conjugates Market Forecast Analysis

7. North America Antibody Drug Conjugates Market Analysis – by Technology

7.1 Cleavable Linker

7.1.1 Overview
7.1.2 Cleavable Linker: North America Antibody Drug Conjugates Market – Revenue and Forecast to 2031 (US$ Million)

7.2 Non-cleavable Linker

7.2.1 Overview
7.2.2 Non-cleavable Linker: North America Antibody Drug Conjugates Market – Revenue and Forecast to 2031 (US$ Million)

8. North America Antibody Drug Conjugates Market Analysis – by Application

8.1 Blood Cancer

8.1.1 Overview
8.1.2 Blood Cancer: North America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)

8.2 Breast Cancer

8.2.1 Overview
8.2.2 Breast Cancer: North America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)

8.3 Ovarian Cancer

8.3.1 Overview
8.3.2 Ovarian Cancer: North America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)

8.4 Urothelial Cancer

8.4.1 Overview
8.4.2 Urothelial Cancer: North America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)

9. North America Antibody Drug Conjugates Market Analysis – by Distribution Channel

9.1 Hospital Pharmacies

9.1.1 Overview
9.1.2 Urothelial Cancer: North America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)

9.2 Retail Pharmacies

9.2.1 Overview
9.2.2 Urothelial Cancer: North America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)

9.3 Online Pharmacies

9.3.1 Overview
9.3.2 Urothelial Cancer: North America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)

10. North America Antibody Drug Conjugates Market – North America Analysis

10.1 North America

10.1.1 North America Antibody Drug Conjugates Market Breakdown, by Key Country, 2023 and 2030 (%)
10.1.1.1 North America Antibody Drug Conjugates Market – Revenue and Forecast Analysis – by Country
10.1.1.1 US: North America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)

10.1.1.1.1 US: North America Antibody Drug Conjugates Market Breakdown, by Technology
10.1.1.1.2 US: North America Antibody Drug Conjugates Market Breakdown, by Application
10.1.1.1.3 US: North America Antibody Drug Conjugates Market Breakdown, by Distribution Channel

10.1.1.2 Canada: North America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)

10.1.1.2.1 Canada: North America Antibody Drug Conjugates Market Breakdown, by Technology
10.1.1.2.2 Canada: North America Antibody Drug Conjugates Market Breakdown, by Application
10.1.1.2.3 Canada: North America Antibody Drug Conjugates Market Breakdown, by Distribution Channel

10.1.1.3 Mexico : North America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)

10.1.1.3.1 Mexico : North America Antibody Drug Conjugates Market Breakdown, by Technology
10.1.1.3.2 Mexico : North America Antibody Drug Conjugates Market Breakdown, by Application
10.1.1.3.3 Mexico : North America Antibody Drug Conjugates Market Breakdown, by Distribution Channel

11. Competitive Landscape

11.1 Heat Map Analysis

11.2 Company Positioning and Concentration

12. North America Antibody Drug Conjugates Market Industry Landscape

12.1 Overview

12.2 Mergers and Acquisitions

12.3 Agreements, Collaborations, and Joint Ventures

12.4 New Product Launches

12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 ADC Therapeutics SA

13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments

13.2 Pfizer Inc

13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments

13.3 Hoffmann-La Roche Ltd

13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments

13.4 ImmunoGen Inc

13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments

13.5 GSK Plc

13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments

13.6 Gilead Sciences Inc

13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments

13.7 AstraZeneca Plc

13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments

13.8 Astellas Pharma Inc

13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments

13.9 RemeGen Co Ltd

13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments

13.10 Takeda Pharmaceutical Co Ltd

13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments

14. Appendix

14.1 About Business Market Insights